SK1798A3 - Benzo£g|quinoline derivatives, a method of producing the same, pharmaceutical composition containing same and their use - Google Patents

Benzo£g|quinoline derivatives, a method of producing the same, pharmaceutical composition containing same and their use Download PDF

Info

Publication number: SK1798A3
Authority: SK; Slovakia
Prior art keywords: group; formula; free base; benzo; acid addition
Prior art date: 1995-07-07

Application number

SK17-98A

Other languages

English (en)

Slovak (sk)

Inventor

Peter Neumann

Paul Pfaeffli

Max P Seiler

Robert Swoboda

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-07

Filing date

1996-07-05

Publication date

1998-06-03

1995-07-07 Priority claimed from GBGB9513880.6A external-priority patent/GB9513880D0/en

1996-02-26 Priority claimed from GBGB9603988.8A external-priority patent/GB9603988D0/en

1996-07-05 Application filed by Novartis Ag filed Critical Novartis Ag

1998-06-03 Publication of SK1798A3 publication Critical patent/SK1798A3/sk

Links

238000000034 method Methods 0.000 title claims description 9
239000008194 pharmaceutical composition Substances 0.000 title claims description 5
125000005605 benzo group Chemical group 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 39
239000003814 drug Substances 0.000 claims abstract description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
150000003839 salts Chemical group 0.000 claims description 19
239000002253 acid Substances 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 15
239000012458 free base Substances 0.000 claims description 13
208000019901 Anxiety disease Diseases 0.000 claims description 12
230000036506 anxiety Effects 0.000 claims description 11
208000020925 Bipolar disease Diseases 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
RFQDDXWZZVRLKO-UHFFFAOYSA-N benzo[g]quinoline Chemical class N1=CC=CC2=CC3=CC=CC=C3C=C21 RFQDDXWZZVRLKO-UHFFFAOYSA-N 0.000 claims description 8
125000004093 cyano group Chemical group *C#N 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 7
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
208000020401 Depressive disease Diseases 0.000 claims description 5
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
-1 bis (4-fluorophenyl) methyl group Chemical group 0.000 claims description 5
239000005557 antagonist Substances 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
125000004430 oxygen atom Chemical group O* 0.000 claims description 4
125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
102000005157 Somatostatin Human genes 0.000 claims description 3
108010056088 Somatostatin Proteins 0.000 claims description 3
229910052783 alkali metal Inorganic materials 0.000 claims description 3
150000001340 alkali metals Chemical class 0.000 claims description 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
229960000553 somatostatin Drugs 0.000 claims description 3
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
239000008024 pharmaceutical diluent Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 6
238000012360 testing method Methods 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
239000002464 receptor antagonist Substances 0.000 description 5
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
229960000623 carbamazepine Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
150000002431 hydrogen Chemical group 0.000 description 4
239000000203 mixture Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
229940044551 receptor antagonist Drugs 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
208000019022 Mood disease Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000006399 behavior Effects 0.000 description 3
229910052744 lithium Inorganic materials 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
201000000980 schizophrenia Diseases 0.000 description 3
206010001488 Aggression Diseases 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010026749 Mania Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
206010041243 Social avoidant behaviour Diseases 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
230000016571 aggressive behavior Effects 0.000 description 2
208000012761 aggressive behavior Diseases 0.000 description 2
230000000949 anxiolytic effect Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
229960004170 clozapine Drugs 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
VWOJSRICSKDKAW-UHFFFAOYSA-N 1-(4-nitrophenyl)piperazine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCNCC1 VWOJSRICSKDKAW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000008811 Agoraphobia Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027951 Mood swings Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
230000036626 alertness Effects 0.000 description 1
238000010640 amide synthesis reaction Methods 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000000228 antimanic agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000021824 exploration behavior Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229940073577 lithium chloride Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
108010082379 somatostatin receptor type 1 Proteins 0.000 description 1
101150029725 sst1 gene Proteins 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/08—Aza-anthracenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

SK17-98A 1995-07-07 1996-07-05 Benzo£g|quinoline derivatives, a method of producing the same, pharmaceutical composition containing same and their use SK1798A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9513880.6A GB9513880D0 (en)	1995-07-07	1995-07-07	Organic compounds
GBGB9603988.8A GB9603988D0 (en)	1996-02-26	1996-02-26	Organic compounds
PCT/EP1996/002969 WO1997003054A1 (fr)	1995-07-07	1996-07-05	DERIVES DE BENZO[g]QUINOLEINE

Publications (1)

Publication Number	Publication Date
SK1798A3 true SK1798A3 (en)	1998-06-03

Family

ID=26307342

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK17-98A SK1798A3 (en)	1995-07-07	1996-07-05	Benzo£g\|quinoline derivatives, a method of producing the same, pharmaceutical composition containing same and their use

Country Status (28)

Country	Link
US (1)	US5885988A (fr)
EP (1)	EP0839136B1 (fr)
JP (1)	JPH11509197A (fr)
KR (1)	KR19990028757A (fr)
CN (1)	CN1193964A (fr)
AR (1)	AR004672A1 (fr)
AT (1)	ATE201199T1 (fr)
AU (1)	AU703325B2 (fr)
BR (1)	BR9609326A (fr)
CA (1)	CA2224436A1 (fr)
CO (1)	CO4750662A1 (fr)
CZ (1)	CZ1698A3 (fr)
DE (1)	DE69612852T2 (fr)
DK (1)	DK0839136T3 (fr)
ES (1)	ES2158327T3 (fr)
GR (1)	GR3036346T3 (fr)
HU (1)	HUP9802937A3 (fr)
IL (1)	IL122854A (fr)
NO (1)	NO310070B1 (fr)
NZ (1)	NZ313606A (fr)
PE (1)	PE1998A1 (fr)
PL (1)	PL324106A1 (fr)
PT (1)	PT839136E (fr)
RU (1)	RU2158738C2 (fr)
SK (1)	SK1798A3 (fr)
TR (1)	TR199800011T1 (fr)
TW (1)	TW357143B (fr)
WO (1)	WO1997003054A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9711043D0 (en)	1997-05-29	1997-07-23	Ciba Geigy Ag	Organic compounds
AU5265599A (en) *	1998-04-08	1999-11-01	Takeda Chemical Industries Ltd.	Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
CA2246791A1 (fr) *	1998-09-01	2000-03-01	Alison Buchan	Traitement de l'endothelium avec des analogues de la somatostatine
US6673799B1 (en) *	1998-09-22	2004-01-06	Yamanouchi Pharmaceutical Co. Ltd.	Cyanophenyl derivative
RU2221785C2 (ru) *	1998-09-22	2004-01-20	Яманоути Фармасьютикал Ко., Лтд.	Гетероциклическое производное, фармацевтическая композиция, его содержащая, и промежуточный продукт
GB9902938D0 (en) *	1999-02-10	1999-03-31	Novartis Ag	Organic compounds
PE20030240A1 (es) *	2001-07-09	2003-04-16	Novartis Ag	DERIVADOS DE BENZO [g] QUINOLINA
FI20031454A0 (fi)	2003-10-06	2003-10-06	Juvantia Pharma Ltd Oy	Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja
KR100594234B1 (ko)	2003-12-05	2006-06-30	삼성전자주식회사	편광 현상을 이용하여 해상도를 향상시킬 수 있는 포토마스크 및 그 제조방법
BRPI0515505A (pt)	2004-09-20	2008-07-29	Xenon Pharmaceuticals Inc	derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
WO2006034341A2 (fr)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
MX2007003321A (es)	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como agentes terapeuticos.
AU2005286728A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AR051026A1 (es)	2004-09-20	2006-12-13	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CA2580857A1 (fr)	2004-09-20	2006-09-28	Xenon Pharmaceuticals Inc.	Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
AU2005286648A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007015216A (es)	2005-06-03	2008-02-22	Xenon Pharmaceuticals Inc	Derivados de aminotiazol y sus usos como agentes terapeuticos.
TWI404702B (zh) *	2007-08-31	2013-08-11	Lundbeck & Co As H	兒茶酚胺衍生物和其前藥
US8067410B2 (en)	2008-06-27	2011-11-29	H. Lundbeck A/S	Phenolic and catecholic amines and prodrugs thereof
US11912687B2 (en)	2017-05-12	2024-02-27	Board of Trustees of the Southern Illinois University	3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
WO2018209267A2 (fr)	2017-05-12	2018-11-15	Board Of Trustees Of The Southern Illinois University On Behalf Of Southern Illinois University Edwardsville	1,2,4-triazoles 3,4,5-trisubstitués et 3-thio-1,2,4-triazoles 3,4,5-trisubstitués et leurs utilisations
US10729710B2 (en)	2017-11-24	2020-08-04	H. Lundbeck A/S	Catecholamine prodrugs for use in the treatment of Parkinson's disease
US11130775B2 (en)	2019-05-20	2021-09-28	H. Lundbeck A/S	Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en)	2019-05-20	2021-09-07	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en)	2019-05-20	2021-08-31	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en)	2019-05-20	2021-11-09	H. Lundbeck A/S	Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
CN113727712B (zh)	2019-05-21	2024-11-15	H.隆德贝克有限公司	用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
CN119707810A (zh)	2019-05-21	2025-03-28	H.隆德贝克有限公司	用于治疗帕金森病的新儿茶酚胺前药
JP7641234B2 (ja)	2019-05-21	2025-03-06	ハー・ルンドベック・アクチエゼルスカベット	パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972971A1 (fr)	2019-05-21	2022-03-30	H. Lundbeck A/S	Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de maladies de parkinson
JP7099717B2 (ja)	2019-09-30	2022-07-12	株式会社理研バイオ	ソマトスタチン受容体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH630902A5 (en) *	1977-01-24	1982-07-15	Sandoz Ag	Process for preparing novel derivatives of 1,2,3,4,4a,10b-hexahydrobenzo(f)isoquinoline.
DE19575006I2 (de) *	1981-10-16	2003-01-09	Novartis Ag	1, 2, 3, 4a, 5, 10, 10a-Octahydrobenzo(g)chinolin-Derivate mit pharmazeutischer Wirkung
SU1109393A1 (ru) *	1983-04-28	1984-08-23	Ордена Трудового Красного Знамени Институт Физики Ан Бсср	Способ получени 9-диэтиламинобензо/ @ /феноксазинона-5 или его производных
HU193979B (en) *	1984-06-12	1987-12-28	Sandoz Ag	Process for producing naphtoxazine derivatives and pharmaceutical compositions containing them
NL8702680A (nl) *	1986-11-21	1988-06-16	Sandoz Ag	Nieuwe benzogchinolinen en werkwijzen voor het bereiden en toepassen van deze verbindingen.
WO1993024471A1 (fr) *	1992-06-02	1993-12-09	Whitby Research, Inc.	Naphtoxazines substitues efficaces en tant que dopaminergiques
WO1994021614A1 (fr) *	1993-03-24	1994-09-29	Merck & Co., Inc.	DERIVES DE 3-PHENANTHRIDINONES SUBSTITUES, UTILISES COMME INHIBITEURS DE LA 5α-REDUCTASE
DE4329776A1 (de) *	1993-09-03	1995-03-09	Sandoz Ag	Naphthoxazine, ihre Herstellung und Verwendung

1996
- 1996-06-12 TW TW085107047A patent/TW357143B/zh active
- 1996-07-05 AU AU66120/96A patent/AU703325B2/en not_active Ceased
- 1996-07-05 WO PCT/EP1996/002969 patent/WO1997003054A1/fr not_active Ceased
- 1996-07-05 CZ CZ9816A patent/CZ1698A3/cs unknown
- 1996-07-05 RU RU98102128/04A patent/RU2158738C2/ru active
- 1996-07-05 IL IL12285496A patent/IL122854A/xx not_active IP Right Cessation
- 1996-07-05 NZ NZ313606A patent/NZ313606A/xx unknown
- 1996-07-05 PT PT96925672T patent/PT839136E/pt unknown
- 1996-07-05 US US08/983,535 patent/US5885988A/en not_active Expired - Fee Related
- 1996-07-05 BR BR9609326A patent/BR9609326A/pt active Search and Examination
- 1996-07-05 CN CN96196551A patent/CN1193964A/zh active Pending
- 1996-07-05 SK SK17-98A patent/SK1798A3/sk unknown
- 1996-07-05 TR TR1998/00011T patent/TR199800011T1/xx unknown
- 1996-07-05 PL PL96324106A patent/PL324106A1/xx unknown
- 1996-07-05 KR KR1019980700056A patent/KR19990028757A/ko not_active Ceased
- 1996-07-05 PE PE1996000517A patent/PE1998A1/es not_active Application Discontinuation
- 1996-07-05 AT AT96925672T patent/ATE201199T1/de not_active IP Right Cessation
- 1996-07-05 EP EP96925672A patent/EP0839136B1/fr not_active Expired - Lifetime
- 1996-07-05 AR ARP960103468A patent/AR004672A1/es unknown
- 1996-07-05 HU HU9802937A patent/HUP9802937A3/hu unknown
- 1996-07-05 CA CA002224436A patent/CA2224436A1/fr not_active Abandoned
- 1996-07-05 ES ES96925672T patent/ES2158327T3/es not_active Expired - Lifetime
- 1996-07-05 DE DE69612852T patent/DE69612852T2/de not_active Expired - Fee Related
- 1996-07-05 CO CO96035363A patent/CO4750662A1/es unknown
- 1996-07-05 DK DK96925672T patent/DK0839136T3/da active
- 1996-07-05 JP JP9505489A patent/JPH11509197A/ja active Pending
1998
- 1998-01-05 NO NO980043A patent/NO310070B1/no not_active IP Right Cessation
2001
- 2001-08-07 GR GR20010401198T patent/GR3036346T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATE201199T1 (de)	2001-06-15
EP0839136B1 (fr)	2001-05-16
WO1997003054A1 (fr)	1997-01-30
IL122854A (en)	2000-12-06
PT839136E (pt)	2001-09-28
GR3036346T3 (en)	2001-11-30
TR199800011T1 (xx)	1998-04-21
PE1998A1 (es)	1998-02-14
TW357143B (en)	1999-05-01
KR19990028757A (ko)	1999-04-15
HUP9802937A2 (hu)	1999-10-28
IL122854A0 (en)	1998-08-16
RU2158738C2 (ru)	2000-11-10
AU6612096A (en)	1997-02-10
JPH11509197A (ja)	1999-08-17
EP0839136A1 (fr)	1998-05-06
NO310070B1 (no)	2001-05-14
HUP9802937A3 (en)	2002-10-28
DK0839136T3 (da)	2001-08-06
AR004672A1 (es)	1999-03-10
US5885988A (en)	1999-03-23
CA2224436A1 (fr)	1997-01-30
NO980043D0 (no)	1998-01-05
CZ1698A3 (cs)	1998-04-15
BR9609326A (pt)	1999-05-25
DE69612852T2 (de)	2001-10-04
NO980043L (no)	1998-01-05
CO4750662A1 (es)	1999-03-31
NZ313606A (en)	1999-07-29
PL324106A1 (en)	1998-05-11
CN1193964A (zh)	1998-09-23
AU703325B2 (en)	1999-03-25
ES2158327T3 (es)	2001-09-01
MX9710530A (es)	1998-03-31
DE69612852D1 (de)	2001-06-21

Publication	Publication Date	Title
SK1798A3 (en)	1998-06-03	Benzo£g\|quinoline derivatives, a method of producing the same, pharmaceutical composition containing same and their use
CN109311871A (zh)	2019-02-05	作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
US20030195193A1 (en)	2003-10-16	Diazepane derivatives or salts thereof
WO2017101803A1 (fr)	2017-06-22	Nouveau double inhibiteur de egfr et de alk
JPWO1999005138A1 (ja)	2002-08-13	複素環式化合物及びそれを有効成分とする抗腫瘍剤
JP5856086B2 (ja)	2016-02-09	薬物製造のためのイソキノロン類の使用、新規なイソキノロン類およびそれらの合成方法
RU2191776C2 (ru)	2002-10-27	Эрголиновые производные, способ их получения, фармацевтическая композиция
IL183594A (en)	2011-12-29	Phenyl-piperazine methanone derivatives, process for their preparation, medicaments containing them and use thereof in the manufacture of medicaments for the treatment of alzheimer's disease
KR20020089372A (ko)	2002-11-29	알파-2 길항제로서의 퀴놀린 유도체
JP2009544657A (ja)	2009-12-17	新規なクロメンおよびチオクロメンカルボキサミド誘導体、その製造方法ならびにその治療適用
TWI259085B (en)	2006-08-01	Piperazine derivatives having SST1 antagonistic activity
US6242448B1 (en)	2001-06-05	Trisubstituted-oxazole derivatives as serotonin ligands
US6391880B1 (en)	2002-05-21	Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
JPH0733743A (ja)	1995-02-03	２−アリール−４−キノリノール誘導体
WO1996020179A1 (fr)	1996-07-04	Derives de la piperazine-2,5-dione utilises comme modulateurs de la resistance multiple aux medicaments
TW201831462A (zh)	2018-09-01	二苯并二氮呯衍生物
CN101921238B (zh)	2012-04-04	取代苯并氮杂环类衍生物的制备及其药理用途
CN120794918A (zh)	2025-10-17	喹唑啉酮类5-ht2a受体拮抗剂及其制备方法和医药用途
MXPA97010530A (en)	1998-10-15	Benzo (a) quinol derivatives
JPH04103572A (ja)	1992-04-06	４―フェニル―２―（１―ピペラジニル）ピリジン誘導体
HK1114841B (en)	2011-04-01	Phenyl-piperazin methanone derivatives
MXPA99001574A (en)	1999-09-20	Fused indolecarboxamides:dopamine receptor subtype specific ligands